|
Pepducins are novel cell-penetrating peptides that act as intracellular modulators of signal transference from receptors to G proteins. Pepducins were first developed at the Tufts Medical Center laboratories of Dr. Athan Kuliopulos and Dr. Lidija Covic. Pepducins utilize lipidated fragments of intracellular G protein-coupled receptor loops to modulate GPCR action in targeted cell-signaling pathways. A Pepducin molecule comprises a short peptide derived from a GPCR intracellular loop tethered to a hydrophobic moiety. This structure allows Pepducin lipopeptides to anchor in the cell membrane lipid bilayer and target the GPCR/G protein interface via a unique intracellular allosteric mechanism. Pepducins for over 15 different GPCRs have been successfully produced, several of which have shown activity in preclinical ''in vivo'' models. An anti-PAR4 pepducin extended bleeding time in mice and protected against systemic platelet activation and thrombosis.〔 A CXCR4 agonist pepducin mobilizes bone marrow hematopoietic cells.〔(【引用サイトリンク】title=Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. )〕 A PAR1 pepducin, PZ-128, has successfully completed phase I clinical trials, and progress continues to be made. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Pepducin」の詳細全文を読む スポンサード リンク
|